Telomerase: A potential therapeutic target for cancer

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 3, 2005, Pages 457-469

  Fletcher, Terace M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

G quadruplex; hTERC; hTERT; Telomerase; Telomere

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACRIDINE DERIVATIVE; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BIBR 1532; BRACO 19; CANCER VACCINE; DNA; DNA BINDING PROTEIN; DOXYCYCLINE; ENZYME INHIBITOR; EPIGALLOCATECHIN GALLATE; FLUOROURACIL; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; MST 312; MYC PROTEIN; NUCLEOSIDE ANALOG; PACLITAXEL; PEPTIDE NUCLEIC ACID; PERYLENE; PORPHYRIN DERIVATIVE; TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERIC REPEAT BINDING FACTOR 2; TELOMESTATIN; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER INHIBITION; CELL AGING; CELL PROLIFERATION; CHROMOSOME; DNA DAMAGE; DNA STRUCTURE; DRUG BINDING SITE; DRUG DESIGN; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME STABILITY; HUMAN; IMMUNOTHERAPY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SOMATIC CELL; TELOMERE; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; NEOPLASMS; TELOMERASE; TELOMERE;

EID: 21244443847     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.3.457     Document Type: Review

References (118)

1. DE LANGE T: Protection of mammalian telomeres. Oncogene (2002) 21:532-540.
2. STEWART SA, BEN-PORATH I, CAREY VJ, O'CONNOR BF, HAHN WC, WEINBERG RA: Erosion of the telomeric single-strand overhang at replicative senescence. Nat. Genet. (2003) 33:492-496.
3. GRIFFITH JD, COMEAU L, ROSENFIELD S et al.: Mammalian telomeres end in a large duplex loop. Cell (1999) 97:503-514.
4. KARLSEDER J, BROCCOLI D, DAI Y, HARDY S, DE LANGE T: p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science (1999) 283:1321-1325.
5. SHAY JW, WRIGHT WE: Telomerase: a target for cancer therapeutics. Cancer Cell (2002) 2:257-265.
6. BLACKBURN EH: Telomere states and cell fates. Nature (2000) 408:53-6.
7. LARRIVEE M, LEBEL C, WELLINGER RJ: The generation of proper constitutive G-tails on yeast telomeres is dependent on the MRX complex. Genes Dev. (2004) 18:1391-1396.
8. VON ZGLINICKI T: Oxidative stress shortens telomeres. Trends Biochem. Sci. (2002) 27:339-344.
9. SHAY JW, WRIGHT WE: Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis (2004) In press.
10. REDDEL RR: Alternative lengthening of telomeres, telomerase, and cancer. Cancer Lett. (2003) 194:155-162.
11. BODNAR AG, OUELLETTE M, FROLKIS M et al.: Extension of life-span by introduction of telomerase into normal human cells. Science (1998) 279:349-352.
12. COUNTER CM, MEYERSON M, EATON EN et al.: Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene (1998) 16:1217-1222.
13. LEE KH, RUDOLPH KL, JU YJ et al.: Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proc. Natl. Acad. Sci. USA (2001) 98:3381-3386.
14. FLETCHER TM: Telomerase - strategies to exploit an important chemotherapeutic target. Expert Opin. Ther. Targets (2001) 5:363-378.
15. OULTON R, HARRINGTON L: A human telomerase-associated nuclease. Mol. Biol. Cell (2004) 15:3244-3256.
16. MELANA SM, HOLLAND JF, POGO BG: Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3′-azido-3′-deoxythymidine. Clin. Cancer Res. (1998) 4:693-696.
17. MO Y, GAN Y, SONG S et al.: Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res. (2003) 63:579-585.
18. MULTANI AS, CHANDRA J, MCCONKER J, SEN S, CABRAL TF, PATHAK S: Cell death in paclitaxel-dependent chinese hamster ovary cells is initiated by the loss of telomeric DNA repeats. Oncol. Res. (1999) 11:455-460.
19. NAKAMURA M, ZHOU XZ, KISHI S, LU KP: Involvement of the telomeric protein Pin2/TRF1 in the regulation of the mitotic spindle. FEBS Lett. (2002) 514:193-198.
20. BROWN T, SIGURDSON E, ROGATKO A, BROCCOLI D: Telomerase inhibition using azidothymidine in the HT-29 colon cancer cell line. Ann. Surg. Oncol. (2003) 10:910-915.
21. HERBERT B, PITTS AE, BAKER SI et al.: Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl. Acad. Sci. USA (1999) 96:14276-14281.
22. ELAYADI AN, DEMIEVILLE A, WANCEWICZ EV, MONIA BP, COREY DR: Inhibition of telomerase by 2′-O-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells. Nucleic Acids Res. (2001) 29:1683-1689.
23. PRUZAN R, PONGRACZ K, GIETZEN K, WALLWEBER G, GRYAZNOV S: Allosteric inhibitors of telomerase: oligonucleotide N3′- > P5′ phosphoramidates. Nucleic Acids Res. (2002) 30:559-568.
24. HERBERT BS, PONGRACZ K, SHAY JW, GRYAZNOV SM, SHEA-HERBERT B: Oligonucleotide N3′- > P5′ phosphoramidates as efficient telomerase inhibitors. Oncogene (2002) 21:638-642.
25. SARETZKI G: Telomerase inhibition as cancer therapy. Cancer Lett. (2003) 194:209-219.
26. ZHANG X, MAR V, ZHOU W, HARRINGTON L, ROBINSON MO: Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. (1999) 13:2388-2399.
27. SHARMA GG, GUPTA A, WANG H et al.: hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene (2003) 22:131-146.
28. NATARAJAN S, CHEN Z, WANCEWICZ EV, MONIA BP, COREY DR: Telomerase reverse transcriptase (hTERT) mRNA and telomerase RNA (hTR) as targets for downregulation of telomerase activity. Oligonucleotides (2004) 14:263-273.
29. KRAEMER K, FUESSEL S, SCHMIDT U et al.: Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin. Cancer Res. (2003) 9:3794-3800.
30. FU XH, ZHANG JS, ZHANG N, ZHANG YD: Combination of telomerase antisense oligonucleotides simultaneously targeting hTR and hTERT produces synergism of inhibition of telomerase activity and growth in human colon cancer cell line. World J. Gastroenterol. (2005) 11:785-790.
31. YOKOYAMA Y, TAKAHASHI Y, SHINOHARA A et al.: Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res. (1998) 58:5406-5410.
32. LUDWIG A, SARETZKI G, HOLM PS et al.: Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res. (2001) 61:3053-3061.
33. HORIKAWA I, BARRETT JC: Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis (2003) 24:1167-76.
34. CONG YS, WRIGHT WE, SHAY JW: Human telomerase and its regulation. Microbiol. Mol. Biol. Rev. (2002) 66:407-425,
35. POMPETTI F, PILLA D, GIANCOLA R: Cancer therapy: switching off oncogenes. Bioessays (2003) 25:104-107.
36. WU KJ, GRANDORI C, AMACKER M et al.: Direct activation of TERT transcription by c-MYC. Nat. Genet. (1999) 21:220-224.
37. XU D, POPOV N, HOU M et al.: Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc. Natl. Acad. Sci. USA (2001) 98:3826-3831.
38. VELDMAN T, LIU X, YUAN H, SCHLEGEL R: Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc. Natl. Acad. Sci. USA (2003) 100:8211-8216.
39. KARLSSON A, GIURIATO S, TANG F, FUNG-WEIER J, LEVAN G, FELSHER DW: Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood (2003) 101:2797-2803.
40. CORNET AM, HANON E, REITER ER et al.: Prostatic androgen repressed message-1 (PARM-1) may play a role in prostatic cell immortalisation. Prostate (2003) 56:220-230.
41. RANGAN A, FEDOROFF OY, HURLEY LH: Induction of duplex to G-quadruplex transition in the c-myc promoter region by a small molecule. J. Biol. Chem. (2001) 276:4640-4646.
42. KYO S, TAKAKURA M, TAIRA T et al.: Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res. (2000) 28:669-677.
43. KANZAWA T, GERMANO IM, KONDO Y, ITO H, KYO S, KONDO S: Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. Br. J. Cancer (2003) 89:922-929.
44. KY0 S, TAKAKURA M, KANAYA T et al.: Estrogen activates telomerase. Cancer Res. (1999) 59:5917-5921.
45. WANG Z, KYO S, MAIDA Y et al.: Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells. Oncogene (2002) 21:3517-3524.
46. MISITI S, NANNI S, FONTEMAGGI G et al.: Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol. Cell. Biol. (2000) 20:3764-3771.
47. WANG S, ZHU J: Evidence for a relief of repression mechanism for activation of the human telomerase reverse transcriptase promoter. J. Biol. Chem. (2003) 278:18842-18850.
48. WANG S, ZHU J: The hTERT gene is embedded in a nuclease-resistant chromatin domain. J. Biol. Chem. (2004) 279:55401-55410.
49. WARNECKE PM, BESTOR TH: Cytosine methylation and human cancer. Curr. Opin. Oncol. (2000) 12:68-73.
50. LOPATINA NG, POOLE JC, SALDANHA SN et al.: Control mechanisms in the regulation of telomerase reverse transcriptase expression in differentiating human teratocarcinoma cells. Biochem. Biophys. Res. Commun. (2003) 306:650-659.
51. LIU L, SALDANHA SN, PATE MS, ANDREWS LG, TOLLEFSBOL TO: Epigenetic regulation of human telomerase reverse transcriptase promoter activity during cellular differentiation. Genes Chromosomes Cancer (2004) 41:26-37.
52. GUILLERET I,BENHATTAR J: Unusual distribution of DNA methylation within the hTERT CpG island in tissues and cell lines. Biochem. Biophys. Res. Commun. (2004) 325:1037-1043.
53. MUKAI S, KONDO Y, KOGA S, KOMATA T, BARNA BP, KONDO S: 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. (2000) 60:4461-4467.
54. YATABE N, KYO S, KONDO S et al.: 2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells. Cancer Gene Ther. (2002) 9:624-630.
55. YEO M, RHA SY, JEUNG HC et al.: Attenuation of telomerase activity by hammerhead ribozyme targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells. Int. J. Cancer (2005) 114:484-489.
56. WONG JM, KUSDRA L, COLLINS K: Subnuclear shuttling of human telomerase induced by transformation and DNA damage. Nat. Cell. Biol. (2002) 4:731-736.
57. NECKERS L: Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. (2002) 8:S55-S61.
58. HOLT SE, AISNER DL, BAUR J et al.: Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev. (1999) 13:817-826.
59. FORSYTHE HL, JARVIS JL, TURNER JW, ELMORE LW, HOLT SE: Stable association of hsp90 and p23, but Not hsp70, with active human telomerase. J. Biol. Chem. (2001) 276:15571-15574.
60. VILLA R, FOLINI M, PORTA CD et al.: Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells. Carcinogenesis (2003) 24:851-859.
61. PETERSON SE, STELLWAGEN AE, DIEDE SJ et al.: The function of a stem-loop in telomerase RNA is linked to the DNA repair protein Ku. Nat. Genet. (2001) 27:64-67.
62. MORAN-JONES K, WAYMAN L, KENNEDY DD et al.: hnRNP A2, a potential ssDNA/RNA molecular adapter at the telomere. Nucleic Acids Res. (2005) 33:486-496.
63. LEI M, PODELL ER, CECH TR: Structure of human POT1 bound to telomeric single-stranded DNA provides a model for chromosome end-protection. Nat. Struct. Mol. Biol. (2004) 11:1223-1229.
64. YE JZ, DONIGIAN JR, VAN OVERBEEK M et al.: TIN2 binds TRF1 and TRF2 simultaneously and stabilizes the TRF2 complex on telomeres. J. Biol. Chem. (2004) 279:47264-47271.
65. LOAYZA D, DE LANGE T: POT1 as a terminal transducer of TRF1 telomere length control. Nature (2003) 424:1013-1018.
66. KELLEHER C, KURTH I, LINGNER J: Human protection of telomeres 1 (POT1) is a negative regulator of telomerase activity in vitro. Mol. Cell. Biol. (2005) 25:808-818.
67. ARMBRUSTER BN, LINARDIC CM, VELDMAN T, BANSAL NP, DOWNIE DL, COUNTER CM: Rescue of an hTERT mutant defective in telomere elongation by fusion with hPot1. Mol. Cell. Biol. (2004) 24:3552-3561.
68. KONDO T, OUE N, YOSHIDA K et al.: Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma. Cancer Res. (2004) 64:523-529.
69. ZHOU XZ, LU KP: The Pin2/TRF1-interacting protein PinX1 is a potent telomerase inhibitor. Cell (2001) 107:347-359.
70. BANIK SS, COUNTER CM: Characterization of interactions between PinX1 and human telomerase subunits hTERT and hTR. J. Biol. Chem. (2004) 279:51745-1748.
71. VAN STEENSEL B, DE LANGE T: Control of telomere length by the human telomeric protein TRF1. Nature (1997) 385:740-3.
72. SMITH S, GIRIAT I, SCHMITT A, DE LANGE T: Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science (1998) 282:1484-1487.
73. SEIMIYA H, MURAMATSU Y, OHISHI T, TSURUO T: Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell (2005) 7:25-37.
74. GELMINI S, POGGESI M, DISTANTE V et al.: Tankyrase, a positive regulator of telomere elongation, is over expressed in human breast cancer. Cancer Lett. (2004) 216:81-87.
75. REZLER EM, BEARSS DJ, HURLEY LH: Telomeres and telomerases as drug targets. Curr. Opin. Pharmacol. (2002) 2:415-423.
76. NEIDLE S, PARKINSON GN: The structure of telomeric DNA. Curr. Opin. Struct. Biol. (2003) 13:275-283.
77. WANG Y, PATEL DJ: Solution structure of the human telomeric repeat d[AG3(T2AG3)3] G-tetraplex. Structure (1993) 1:263-282.
78. ZAHLER AM, WILLIAMSON JR, CECH TR, PRESCOTT DM: Inhibition of telomerase by G-quartet DNA structures. Nature (1991) 350:718-720.
79. FLETCHER TM, SUN D, SALAZAR M, HURLEY LH: Effect of DNA secondary structure on human telomerase activity. Biochemistry (1998) 37:5536-5541.
80. SUN D, LOPEZ-GUAJARDO CC, QUADA J, HURLEY LH, VON HOFF DD: Regulation of catalytic activity and processivity of human telomerase. Biochemistry (1999) 38:4037-4044.
81. CRABBE L, VERDUN RE, HAGGBLOM CI, KARLSEDER J: Defective telomere tagging strand synthesis in cells lacking WRN helicase activity. Science (2004) 306:1951-1953.
82. HICKSON ID: RecQ helicases: caretakers of the genome. Nat. Rev. Cancer (2003) 3:169-78.
83. YANEZ G, KHAN S, LOCOVEI A, PEDROSO I, FLETCHER T: DNA scructure-dependent recruitment of telomeric proteins to single-stranded/ double-stranded DNA junctions. Biochem. Biophys. Res. Commun. (2005) in press:
84. MIYOSHI D, MATSUMURA S, NAKANO S, SUGIMOTO N: Duplex dissociation of telomere DNAs induced by molecular crowding. J. Am. Chem. Soc. (2004) 126:165-169.
85. KERWIN SM: G-Quadruplex DNA as a target for drug design. Curr. Pharm. Des. (2000) 6:441-478.
86. SUN D, THOMPSON B, CATHERS BE et al.: Inhibition of human telomerase by a G-quadruplex-interactive compound. J. Med. Chem. (1997) 40:2113-2116.
87. PERRY PJ, GOWAN SM, RESZKA AP et al.: 1,4- and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase. J. Med. Chem. (1998) 41:3253-3260.
88. TANIOUS FA, JENKINS TC, NEIDLE S, WILSON WD: Substituent position dictates the intercalative DNA-binding mode for anthracene-9,10-dione antitumor drugs. Biochemistry (1992) 31:11632-11640.
89. IZBICKA E, WHEELHOUSE RT, RAYMOND E et al.: Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res. (1999) 59:639-644.
90. FEDOROFF OY, SALAZAR M, HAN H, CHEMERIS VV, KERWIN SM, HURLEY LH: NMR-Based model of a telomerase-inhibiting compound bound to G-quadruplex DNA.PG - 12367-74. Biochemistry (1998) 37:12367-12374.
91. KERN JT, THOMAS PW, KERWIN SM: The relationship between ligand aggregation and G-quadruplex DNA selectivity in a series of 3,4,9,10-perylenetetracarboxylic acid diimides. Biochemistry (2002) 41:11379-11389.
92. READ M, HARRISON RJ, ROMAGNOLI B et al.: Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors. Proc. Natl. Acad. Sci. USA (2001) 98:4844-4849.
93. LI JL, HARRISON RJ, RESZKA AP et al.: Inhibition of the Bloom's and Werner's syndrome helicases by G-quadruplex interacting ligands. Biochemistry (2001) 40:15194-15202.
94. STAVROPOULOS DJ, BRADSHAW PS, LI X et al.: The Bloom syndrome helicase BLM interacts with TRF2 in ALT cells and promotes telomeric DNA synthesis. Hum. Mol. Genet. (2002) 11:3135-3144.
95. INCLES CM, SCHULTES CM, KEMPSKI H, KOEHLER H, KELLAND LR, NEIDLE S: A G-quadruplex telomere targeting agent produces p16-associated senescence and chromosomal fusions in human prostate cancer cells. Mol. Cancer Ther. (2004) 3:1201-1206.
96. RIOU JF, GUITTAT L, MAILLIET P et al.: Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands. Proc. Natl. Acad. Sci. USA (2002) 99:2672-2677.
97. GOMEZ D, LEMARTELEUR T, LACROIX L, MAILLIET P, MERGNY JL, RIOU JF: Telomerase downregulation induced by the G-quadruplex ligand 12459 in A549 cells is mediated by hTERT RNA alternative splicing. Nucleic Acids Res. (2004) 32:371-379.
98. SHIN-YA K, WIERZBA K, MATSUO K et al.: Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus. J. Am. Chem. Soc. (2001) 123: 1262-1263.
99. KIM MY, VANKAYALAPATI H, SHIN-YA K, WIERZBA K, HURLEY LH: Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. J. Am. Chem. Soc. (2002) 124:2098-2099.
100. KIM MY, GLEASON-GUZMAN M, IZBICKA E, NISHIOKA D, HURLEY LH: The Different Biological Effects of Telomestatin and TMPyP4 Can Be Attributed to Their Selectivity for Interaction with Intramolecular or Intermolecular G-Quadruplex Structures. Cancer Res. (2003) 63:3247-3256.
101. TAUCHI T, SHIN-YA K, SASHIDA G et al.: Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. Oncogene (2003) 22:5338-5347.
102. SUMI M, TAUCHI T, SASHIDA G et al.: A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia. Int. J. Oncol. (2004) 24:1481-1487.
103. GOMEZ D, PATERSKI R, LEMARTELEUR T, SHIN-YA K, MERGNY JL, RIOU JF: Interaction of telomestatin with the telomeric single-strand overhang. J. Biol. Chem. (2004) 279:41487-41494.
104. VONDERHEIDE RH, ANDERSON KS, HAHN WC, BUTLER MO, SCHULTZE JL, NADLER LM: Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin. Cancer Res. (2001) 7:3343-3348.
105. VONDERHEIDE RH, DOMCHEK SM, SCHULTZE JL et al.: Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin. Cancer Res. (2004) 10:828-839.
106. BITTON RJ: Cancer vaccines: a critical review on clinical impact. Curr. Opin. Mol. Ther. (2004) 6:17-26.
107. RODRIGUEZ PC, ZEA AH, OCHOA AC: Mechanisms of tumor evasion from the immune response. Cancer Chemother Biol. Response Modif. (2003) 21:351-364.
108. ZOU W, LUO C, ZHANG Z et al.: A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene (2004) 23:457-464.
109. WIRTH T, ZENDER L, SCHULTE B et al.: A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res. (2003) 63:3181-3188.
110. SAVAGE HE, ROSSEN RD, HERSH EM, FREEDMAN RS, BOWEN JM, PLAGER C: Antibody development to viral and allogeneic tumor cell-associated antigens in patients with malignant melanoma and ovarian carcinoma treated with lysates of virus-infected tumor cells. Cancer Res. (1986) 46:2127-33.
111. LAWLEY PD, PHILLIPS DH: DNA adducts from chemotherapeutic agents. Mutat. Res. (1996) 355:13-40.
112. ESTELLER M, HERMAN JG: Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene (2004) 23:1-8.
113. BRADSHAW PS, STAVROPOULOS DJ, MEYN MS: Human telomeric protein TRF2 associates with genomic double-strand breaks as an early response to DNA damage. Nat. Genet. (2005) 37:193-197.
114. KLAPPER W, QIAN W, SCHULTE C, PARWARESCH R: DNA damage transiently increases TRF2 mRNA expression and telomerase activity. Leukemia (2003) 17:2007-2015.
115. PETERSON SE, STELLWAGEN AE, DIEDE SJ et al.: The function of a stem-loop in telomerase RNA is linked to the DNA repair protein Ku. Nature Genet. (2001) 27:64-67.
116. VARLEY H, DI S, SCHERER SW, ROYLE NJ: Characterization of terminal deletions at 7q32 and 22q13.3 healed by De novo telomere addition. Am. J. Hum. Genet. (2000) 67:610-622.
117. RAHMAN R, LATONEN L, WIMAN KG: hTERT antagonizes p53-induced apoptosis independently of telomerase activity. Oncogene (2005) 24:1320-1327.
118. EL-DALY H, KULL M, ZIMMERMANN S, PANTIC M, WALLER CF, MARTENS UM: Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood (2005) 105:1742-1749.